Paratek Pharmaceuticals To Acquire Optinose for Up To $330 Million

Reuters
20 Mar
March 19 (Reuters) - Paratek Pharmaceuticals: :
*PARATEK PHARMACEUTICALS TO ACQUIRE OPTINOSE, CREATING SIGNIFICANT COMMERCIAL EXPANSION OPPORTUNITIES FOR XHANCE® IN CHRONIC RHINOSINUSITIS $(CRS)$
*PARATEK PHARMACEUTICALS - TOTAL TRANSACTION VALUE OF UP TO $330 MILLION
*PARATEK PHARMACEUTICALS- POTENTIAL CONSIDERATION OF UP TO $14 PER SHARE, INCLUDING UPFRONT CONSIDERATION OF $9 PER SHARE

((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))
Source Date/Time = 20-MAR-202501:25:02.19 GMT

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10